Example: Heart Attack
Clinical Trials on Beta-galactosidase-1 Deficiency
Total 1 results
-
NCT04713475RecruitingConditions: GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
Show vendors
Medical Conditions
- COVID-19
- Monkeypox
- 2q37 Deletion Syndrome
- Capillary Malformation-arteriovenous Malformation Syndrome
- Essential Tremor
- Heroin Dependence
- Malignant Peripheral Nerve Sheath Tumor
- Pheochromocytoma
- Polycystic Kidney Diseases
- Primary Hyperoxaluria Type 1
- Pseudolymphoma
- Spondylolisthesis
- Tick Bites
- Wasting Syndrome
- Wolman Disease
- View Full List
Sponsors and Collaborators
- Amber Therapeutics Ltd
- Center Eugene Marquis
- County Durham and Darlington NHS Foundation Trust
- Daejeon St. Mary's hospital
- Efemoral Medical, Inc.
- German AML Cooperative Group
- London South Bank University
- National Hepatology & Tropical Medicine Research Institute
- PBB Entrepreneur Ltd.
- Showa University
- Summit Doppler Systems, Inc.
- Swiss Cancer League
- Taiwan Epidemiology Association
- View Full List